
|Videos|December 27, 2022
RCC Trial Review: COSMIC-313
Author(s)Rana R. McKay, MD
Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
5








































